Manufacturer of Controlled Substances Registration: Alltech Associates, Inc., 66407-66408 [2014-26448]
Download as PDF
<![CDATA[
66407
mstockstill on DSK4VPTVN1PROD with NOTICES
Federal Register / Vol. 79, No. 216 / Friday, November 7, 2014 / Notices
moot. Here, while various controlled
substances were seized, the Government
subsequently provided registrant with
the opportunity to transfer the
controlled substances to a registered
successor in interest. See 21 U.S.C.
§ 824(g). Thus, to the extent the
controlled substances had any market
value—which appears highly unlikely
anyway given that they were in
prescription vials and not sealed
commercial containers—the
Government disclaimed any interest in
them. Registrant’s failure to respond to
the Government’s offer itself constitutes
a waiver of any claim to title to the
drugs. Thus, there is no need to issue a
decision on the merits to adjudicate the
issue of title to the drugs.
To the extent the issuance of the
Immediate Suspension has harmed
Registrant’s reputation and may result
in his having to report this action on
future applications for a DEA
registration or a state license, Registrant
was provided with the opportunity to
request a hearing and challenge the
basis of the Government’s action.
Registrant did not, however, seek to do
so. See Richard C. Quigley, 79 FR 50945,
50947 (2014) (rejecting Government’s
contention that ISO case was not moot
because of potential harm to physician’s
reputation when physician did not
request a hearing).
It is acknowledged that several federal
appeals courts have held that ‘‘the mere
possibility of adverse collateral
consequences is sufficient to preclude a
finding of mootness.’’ In re Surrick, 338
F.3d 224, 230 (3d Cir. 2003) (quoting
Dailey v. Vought Aircraft Co., 141 F.3d
224, 228 (5th Cir. 1998)). But in those
cases, which involved sanctions
imposed by courts on attorneys, the
person who was sanctioned at least
cared enough to litigate. Not so here. So
too, this case stands in contrast to those
cases where the Agency has ruled on the
validity of a suspension order
notwithstanding that a registrant
allowed his/her registration to expire
and failed to file a renewal application.
See Lockridge, 71 FR at 77797 (holding
case not moot where registrant subject
to ISO did not allow registration to
expire until after receiving adverse
recommended decision from ALJ); see
also Nirmal Saran & Nisha Saran, 73 FR
7827, 7835 n.29 (2008) (holding case not
moot where during proceeding,
registrants’ registrations expired but
registrants asserted that they intended to
remain in professional practice and had
attempted to renew their registrations
online but been prevented from doing
so). Accordingly, I conclude that this
case is moot. See Tin T. Win, 78 FR
52802 (2013) (holding ISO proceeding
VerDate Sep<11>2014
19:12 Nov 06, 2014
Jkt 235001
moot where physician, who allowed her
registration to expire, failed to request a
hearing and no controlled substances
had been seized); Robert Charles Ley, 76
FR 20033 (2011) (holding ISO
proceeding moot where physician
eventually waived his right to a hearing
and no controlled substances had been
seized).
compliance with state and local laws,
and reviewed the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above-named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed:–
Order
Controlled substance
Pursuant to the authority vested in me
by 21 U.S.C. § 824(a), as well as 28 CFR
0.100(b) and 0.104, I order that the
Order to Show Cause and Immediate
Suspension of Registration issued to
Martin L. Korn, M.D., be, and it hereby
is, dismissed. This Order is effective
immediately.
Dated: October 23, 2014.
Thomas M. Harrigan,
Deputy Administrator.
[FR Doc. 2014–26447 Filed 11–6–14; 8:45 am]
BILLING CODE 4410–09–P
JUSTICE DEPARTMENT
Drug Enforcement Administration
[Docket No. DEA–392]
Manufacturer of Controlled
Substances Registration: Alltech
Associates, Inc.
ACTION:
Notice of registration.
Alltech Associates, Inc.,
applied to be registered as a
manufacturer of certain basic classes of
controlled substances. The DEA grants
Alltech Associates, Inc. registration as a
manufacturer of those controlled
substances.
SUMMARY:
By notice
dated May 2, 2014, and published in the
Federal Register on May 15, 2014, 79
FR 27936, Alltech Associates, Inc., 2051
Waukegan Road, Deerfield, Illinois
60015, applied to be registered as a
manufacturer of certain basic classes of
controlled substances. No comments or
objections were submitted to this notice.
The Drug Enforcement
Administration (DEA) has considered
the factors in 21 U.S.C. 823(a) and
determined that the registration of
Alltech Associates, Inc., to manufacture
the basic classes of controlled
substances is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971. The DEA investigated the
company’s maintenance of effective
controls against diversion by inspecting
and testing the company’s physical
security systems, verified the company’s
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
Methcathinone (1237) ..................
N-Ethylamphetamine (1475) ........
N,N-Dimethylamphetamine (1480)
4-Methylaminorex (cis isomer)
(1590).
Gamma
Hydroxybutyric
Acid
(2010).
Alpha-ethyltryptamine (7249) .......
Lysergic acid diethylamide (7315)
2C-T-7
(2,5-Dimethoxy-4-(n)propylthiophenethylamine)
(7348).
Tetrahydrocannabinols (7370) .....
Mescaline (7381) ..........................
2C-T-2
(2-(4-Ethylthio-2,5dimethoxyphenyl)ethanamine)
(7385).
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
4-Methyl-2,5dimethoxyamphetamine (7395).
2,5-Dimethoxyamphetamine
(7396).
2,5-Dimethoxy-4ethylamphetamine (7399).
3,4-Methylenedioxyamphetamine
(7400).
N-Hydroxy-3,4methylenedioxyamphetamine
(7402).
3,4-Methylenedioxy-N-ethylamphetamine (7404).
3,4-Methylenedioxymethamphetamine (7405).
4-Methoxyamphetamine (7411) ...
5-Methoxy-N-Ndimethyltryptamine (7431).
Alpha-methyltryptamine (7432) ....
Bufotenine (7433) .........................
Diethyltryptamine (7434) ..............
Dimethyltryptamine (7435) ...........
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
5-Methoxy-N,Ndiisopropyltryptamine (7439).
N-Ethyl-1-phenylcyclohexylamine
(7455).
1-(1-Phenylcyclohexyl)pyrrolidine
(7458).
1-[1-(2Thienyl)cyclohexyl]piperidine
(7470).
2C-E
(2-(2,5-Dimethoxy-4ethylphenyl)ethanamine) (7509).
2C-H
(2-(2,5Dimethoxyphenyl)ethanamine)
(7517).
2C-I
(2-(4-lodo-2,5dimethoxyphenyl)ethanamine)
(7518).
E:\FR\FM\07NON1.SGM
07NON1
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
66408
Federal Register / Vol. 79, No. 216 / Friday, November 7, 2014 / Notices
Controlled substance
Schedule
2C-C
(2-(4-Chloro-2,5dimethoxyphenyl)ethanamine
(7519).
2C-T-4
(2-(4-Isopropylthio)-2,5dimethoxyphenyl)ethanamine)
(7532).
Dihydromorphine (9145) ...............
Heroin (9200) ...............................
Normorphine (9313) .....................
Methamphetamine (1105) ............
1-Phenylcyclohexylamine (7460)
Phencyclidine (7471) ....................
Phenylacetone (8501) ..................
1Piperidinocyclohexanecarbonitrile (8603).
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Ecgonine (9180) ...........................
Meperidine intermediate-B (9233)
Morphine (9300) ...........................
Noroxymorphone (9668) ..............
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
high purity drug standards used for
analytical applications only in clinical,
toxicological, and forensic laboratories,
and for distribution to its customers.
Dated: October 23, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2014–26448 Filed 11–6–14; 8:45 am]
PRAViewICR?ref_nbr=201410-1225-001
(this link will only become active on the
day following publication of this notice)
or by contacting Michel Smyth by
telephone at 202–693–4129, TTY 202–
693–8064, (these are not toll-free
numbers) or by email at DOL_PRA_
PUBLIC@dol.gov.
Submit comments about this request
by mail or courier to the Office of
Information and Regulatory Affairs,
Attn: OMB Desk Officer for DOL–DM,
Office of Management and Budget,
Room 10235, 725 17th Street NW.,
Washington, DC 20503; by Fax: 202–
395–5806 (this is not a toll-free
number); or by email: OIRA_
submission@omb.eop.gov. Commenters
are encouraged, but not required, to
send a courtesy copy of any comments
by mail or courier to the U.S.
Department of Labor-OASAM, Office of
the Chief Information Officer, Attn:
Departmental Information Compliance
Management Program, Room N1301,
200 Constitution Avenue NW.,
Washington, DC 20210; or by email:
DOL_PRA_PUBLIC@dol.gov.
FOR FURTHER INFORMATION CONTACT:
Contact Michel Smyth by telephone at
202–693–4129, TTY 202–693–8064,
(these are not toll-free numbers) or by
email at DOL_PRA_PUBLIC@dol.gov.
Authority: 44 U.S.C. 3507(a)(1)(D).
BILLING CODE 4410–09–P
This ICR
seeks to extend PRA authority for the
Equal Access to Justice Act (EAJA)
information collection requirements for
the DOL codified in regulations 29 CFR
part 16, subpart B. The EAJA provides
for payment of fees and expenses to
eligible parties who have prevailed
against an agency in certain
administrative proceedings. In order to
obtain an award, the statute and
associated DOL regulations require the
filing of an application. Other agencies
may have their own EAJA regulations.
This information collection is
authorized under 5 U.S.C. 504(d)(1)(B).
This information collection is subject
to the PRA. A Federal agency generally
cannot conduct or sponsor a collection
of information, and the public is
generally not required to respond to an
information collection, unless it is
approved by the OMB under the PRA
and displays a currently valid OMB
Control Number. In addition,
notwithstanding any other provisions of
law, no person shall generally be subject
to penalty for failing to comply with a
collection of information that does not
display a valid Control Number. See 5
CFR 1320.5(a) and 1320.6. The DOL
obtains OMB approval for this
information collection under Control
Number 1225–0013.
SUPPLEMENTARY INFORMATION:
DEPARTMENT OF LABOR
Office of the Secretary
Agency Information Collection
Activities; Submission for OMB
Review; Comment Request; Equal
Access to Justice Act
ACTION:
Notice.
The Department of Labor
(DOL) is submitting the information
collection request (ICR) titled, ‘‘Equal
Access to Justice Act,’’ to the Office of
Management and Budget (OMB) for
review and approval for continued use,
without change, in accordance with the
Paperwork Reduction Act of 1995
(PRA), 44 U.S.C. 3501 et seq. Public
comments on the ICR are invited.
DATES: The OMB will consider all
written comments that agency receives
on or before December 8, 2014
ADDRESSES: A copy of this ICR with
applicable supporting documentation;
including a description of the likely
respondents, proposed frequency of
response, and estimated total burden
may be obtained free of charge from the
RegInfo.gov Web site at https://
www.reginfo.gov/public/do/
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
19:12 Nov 06, 2014
Jkt 235001
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
OMB authorization for an ICR cannot
be for more than three (3) years without
renewal, and the current approval for
this collection is scheduled to expire on
January 31, 2015. The DOL seeks to
extend PRA authorization for this
information collection for three (3) more
years, without any change to existing
requirements. The DOL notes that
existing information collection
requirements submitted to the OMB
receive a month-to-month extension
while they undergo review. For
additional substantive information
about this ICR, see the related notice
published in the Federal Register on
August 18, 2014 (79 FR 48770).
Interested parties are encouraged to
send comments to the OMB, Office of
Information and Regulatory Affairs at
the address shown in the ADDRESSES
section within thirty (30) days of
publication of this notice in the Federal
Register. In order to help ensure
appropriate consideration, comments
should mention OMB Control Number
1225–0013. The OMB is particularly
interested in comments that:
• Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
• Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
• Enhance the quality, utility, and
clarity of the information to be
collected; and
• Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses.
Agency: DOL–DM.
Title of Collection: Equal Access to
Justice Act.
OMB Control Number: 1225–0013.
Affected Public: Individuals or
Households; Private Sector—businesses
or other for-profits, farms, and not-forprofit institutions; and State, Local, and
Tribal Governments.
Total Estimated Number of
Respondents: 10.
Total Estimated Number of
Responses: 10.
Total Estimated Annual Time Burden:
50 hours.
Total Estimated Annual Other Costs
Burden: $23.
E:\FR\FM\07NON1.SGM
07NON1
]]>Agencies
[Federal Register Volume 79, Number 216 (Friday, November 7, 2014)]
[Notices]
[Pages 66407-66408]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-26448]
-----------------------------------------------------------------------
JUSTICE DEPARTMENT
Drug Enforcement Administration
[Docket No. DEA-392]
Manufacturer of Controlled Substances Registration: Alltech
Associates, Inc.
ACTION: Notice of registration.
-----------------------------------------------------------------------
SUMMARY: Alltech Associates, Inc., applied to be registered as a
manufacturer of certain basic classes of controlled substances. The DEA
grants Alltech Associates, Inc. registration as a manufacturer of those
controlled substances.
SUPPLEMENTARY INFORMATION: By notice dated May 2, 2014, and published
in the Federal Register on May 15, 2014, 79 FR 27936, Alltech
Associates, Inc., 2051 Waukegan Road, Deerfield, Illinois 60015,
applied to be registered as a manufacturer of certain basic classes of
controlled substances. No comments or objections were submitted to this
notice.
The Drug Enforcement Administration (DEA) has considered the
factors in 21 U.S.C. 823(a) and determined that the registration of
Alltech Associates, Inc., to manufacture the basic classes of
controlled substances is consistent with the public interest and with
United States obligations under international treaties, conventions, or
protocols in effect on May 1, 1971. The DEA investigated the company's
maintenance of effective controls against diversion by inspecting and
testing the company's physical security systems, verified the company's
compliance with state and local laws, and reviewed the company's
background and history.
Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21
CFR 1301.33, the above-named company is granted registration as a bulk
manufacturer of the basic classes of controlled substances listed:-
------------------------------------------------------------------------
Controlled substance Schedule
------------------------------------------------------------------------
Methcathinone (1237)....................... I
N-Ethylamphetamine (1475).................. I
N,N-Dimethylamphetamine (1480)............. I
4-Methylaminorex (cis isomer) (1590)....... I
Gamma Hydroxybutyric Acid (2010)........... I
Alpha-ethyltryptamine (7249)............... I
Lysergic acid diethylamide (7315).......... I
2C-T-7 (2,5-Dimethoxy-4-(n)- I
propylthiophenethylamine) (7348).
Tetrahydrocannabinols (7370)............... I
Mescaline (7381)........................... I
2C-T-2 (2-(4-Ethylthio-2,5- I
dimethoxyphenyl)ethanamine) (7385).
4-Bromo-2,5-dimethoxyamphetamine (7391).... I
4-Bromo-2,5-dimethoxyphenethylamine (7392). I
4-Methyl-2,5-dimethoxyamphetamine (7395)... I
2,5-Dimethoxyamphetamine (7396)............ I
2,5-Dimethoxy-4-ethylamphetamine (7399).... I
3,4-Methylenedioxyamphetamine (7400)....... I
N-Hydroxy-3,4-methylenedioxyamphetamine I
(7402).
3,4-Methylenedioxy-N-ethylam-phetamine I
(7404).
3,4-Methylenedioxymetham-phetamine (7405).. I
4-Methoxyamphetamine (7411)................ I
5-Methoxy-N-N-dimethyltryptamine (7431).... I
Alpha-methyltryptamine (7432).............. I
Bufotenine (7433).......................... I
Diethyltryptamine (7434)................... I
Dimethyltryptamine (7435).................. I
Psilocybin (7437).......................... I
Psilocyn (7438)............................ I
5-Methoxy-N,N-diisopropyltryptamine (7439). I
N-Ethyl-1-phenylcyclohexylamine (7455)..... I
1-(1-Phenylcyclohexyl)pyrrolidine (7458)... I
1-[1-(2-Thienyl)cyclohexyl]piperidine I
(7470).
2C-E (2-(2,5-Dimethoxy-4- I
ethylphenyl)ethanamine) (7509).
2C-H (2-(2,5-Dimethoxyphenyl)ethanamine) I
(7517).
2C-I (2-(4-lodo-2,5-
dimethoxyphenyl)ethanamine) (7518).
[[Page 66408]]
2C-C (2-(4-Chloro-2,5- I
dimethoxyphenyl)ethanamine (7519).
2C-T-4 (2-(4-Isopropylthio)-2,5- I
dimethoxyphenyl)ethanamine) (7532).
Dihydromorphine (9145)..................... I
Heroin (9200).............................. I
Normorphine (9313)......................... I
Methamphetamine (1105)..................... II
1-Phenylcyclohexylamine (7460)............. II
Phencyclidine (7471)....................... II
Phenylacetone (8501)....................... II
1-Piperidinocyclohexanecarbonitrile (8603). II
Cocaine (9041)............................. II
Codeine (9050)............................. II
Dihydrocodeine (9120)...................... II
Ecgonine (9180)............................ II
Meperidine intermediate-B (9233)........... II
Morphine (9300)............................ II
Noroxymorphone (9668)...................... II
------------------------------------------------------------------------
The company plans to manufacture high purity drug standards used
for analytical applications only in clinical, toxicological, and
forensic laboratories, and for distribution to its customers.
Dated: October 23, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2014-26448 Filed 11-6-14; 8:45 am]
BILLING CODE 4410-09-P
